Physician profile
Ronjay Rakkhit
NPI 1982644498
$12,728.45
in general payments reported to CMS, 2019-2025
65 companies · $1,392 in 2025
The $1,392 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,271 · 2020: $1,131 · 2021: $872 · 2022: $3,597 · 2023: $1,912 · 2024: $1,555 · 2025: $1,392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,584 · Grant: $235 · Education: $38.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,584.09 |
| Grant | $235.20 |
| Education | $38.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Pharmaceuticals LLC | $2,259.94 | 2021-2022 | |
| Pfizer INC. | $959.84 | 2019-2025 | |
| Janssen Biotech, INC. | $929.06 | 2019-2025 | Rybrevant, Erleada, Akeega |
| Novartis Pharmaceuticals Corporation | $766.11 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $721.91 | 2019-2025 | Opdualag, Opdivo |
| Amgen INC. | $613.23 | 2019-2023 | Kyprolis, Vectibix, Nplate |
| Celgene Corporation | $591.40 | 2021-2025 | Pomalyst, Reblozyl, Opdualag |
| Genzyme Corporation | $439.36 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $389.22 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Genentech USA, INC. | $373.96 | 2019-2023 | Tecentriq, Polivy, Venclexta |
| Abbvie INC. | $326.90 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $322.37 | 2019-2022 | |
| Gilead Sciences, INC. | $284.57 | 2019-2025 | Trodelvy |
| Tempus Ai, INC | $276.42 | 2024-2025 | Xt Cdx |
| Glaxosmithkline, LLC. | $238.93 | 2021-2025 | Jemperli, Zejula, Ojjaara |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronjay Rakkhit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.